Evaluate the Glycemic Control of CKD-501 in Type 2 Diabetes Mellitus

PHASE2CompletedINTERVENTIONAL
Enrollment

214

Participants

Timeline

Start Date

July 31, 2007

Primary Completion Date

October 31, 2008

Study Completion Date

October 31, 2008

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

CKD-501 0.5mg

0.5 mg/tablet, orally, 1 tablet once daily for 8 weeks

DRUG

CKD-501 1mg

1 mg/tablet, orally, 1 tablet once daily for 8 weeks

DRUG

CKD-501 2mg

2 mg/tablet, orally, 1 tablet once daily for 8 weeks

DRUG

Placebo

orally, 1 tablet once daily for 8 weeks

Trial Locations (8)

Unknown

The Inje University Medical Center, Busan

The Yeungnam University Hospital, Daegu

The Chtholic University of Korea Uijeongbu St. Mary's Hospital, Gyeonggi-do

The Seoul National Univertisy Bundang Hospital, Gyeonggi-do

The Wonju Christian Hospital, Kangwon-Do

The Inje University Sanggye-Paik Hospital, Seoul

The Korea University Anam Hospital, Seoul

The Samsung Medical Center, Seoul

Sponsors
All Listed Sponsors
lead

Chong Kun Dang Pharmaceutical

INDUSTRY